South Dakota Patent of the Month – July 2024
ImmutriX Therapeutics, Inc. has pioneered a novel method for decontaminating bodily fluids with their innovative cartridge design. This advanced technology promises significant advancements in medical treatments by effectively removing harmful components from bodily fluids, ensuring enhanced therapeutic outcomes.
Central to ImmutriX’s invention is the specialized cartridge, meticulously engineered to optimize the purification process. The cartridge features a unique configuration, comprising a cartridge body that houses an adsorptive material critical for filtering substances from bodily fluids. An end segment seals one end of the cartridge, designed with a circular face in an outwardly truncated conical shape. This design creates an internal conical space, strategically directing the entry of bodily fluid through a tangential inlet. This ingenious setup not only decelerates the fluid within the conical space but also ensures perpendicular contact with the adsorptive material, maximizing filtration efficiency.
The method begins with attaching the cartridge to both the input and output for bodily fluid flow, establishing a seamless pathway for fluid processing. As bodily fluid passes through the cartridge, contaminants and harmful substances are effectively filtered out, producing a purified, decontaminated bodily fluid ready for therapeutic use.
ImmutriX’s invention supports versatile application scenarios, from clinical treatments requiring precise fluid purification to research environments demanding high purity standards. The inclusion of optional components like pumps and pressure sensors further enhances operational control and efficiency, ensuring optimal performance across various medical settings.
ImmutriX’s innovative cartridge design represents a significant leap forward in medical technology. By harnessing the power of advanced material science and engineering, their method promises to elevate standards in fluid purification, offering new possibilities for improving patient care and advancing medical research. This invention not only meets the current needs for selective removal of harmful molecules from bodily fluids but also sets a foundation for future innovations in therapeutic treatments and healthcare technologies.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
